CAS NO: | 1523404-29-6 |
包装 | 价格(元) |
10 mM * 1 mL in Ethanol | 电议 |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Vps34-IN-2 is a novel, potent and selective inhibitor ofVps34withIC50s of 2 and 82 nM on theVps34enzymatic assay and the GFP-FYVE cellular assay, respectively[1]. Vps34-IN-2 shows antiviral activity againstSARS-CoV-2(IC50of 3.1 μM),HCoV-229E(IC50of 0.7 μM) andHCoV-OC43[2]. | ||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||
体外研究 (In Vitro) | Vps34-IN-2 (Compound 31) displays IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively. Vps34-IN-2 exhibits selectivity against mTOR (IC50>10 μM) and class I PI3Ks (IC50values of 2.7, 4.5, 2.5, and >10 μM on PI3K α, β, δ, γ isoforms, respectively)[1]. | ||||||||||||||||
体内研究 (In Vivo) | After administration by the intravenous (iv) route, Vps34-IN-2 (Compound 31) concentrations are quantifiable up to 6, 8, and 24 h (last sampling time) depending on animals. After oral administration (po), Vps34-IN-2 is rapidly absorbed with maximal plasma concentrations observed at 0.5 h and a bioavailability of 85%. Slight rebounds of concentrations are observed at 4 and 8 h after oral dosing with no obvious explanation. After iv injection of Vps34-IN-2 at 3 mg/kg, plasma clearance is found moderate (i.e., 2.3 L/h/kg), corresponding to 44% of hepatic blood flow in this species, volume of distribution at steady state is moderate, and terminal elimination half-life is short[1]. | ||||||||||||||||
分子量 | 402.41 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C18H25F3N4O3 | ||||||||||||||||
CAS 号 | 1523404-29-6 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: Ethanol : 50 mg/mL(124.25 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|